title: Top stories of 2008. Beyond abacavir/3TC: good news on first-line regimens.
abstract: Positive data emerged this year to support the use of boosted atazanavir and boosted darunavir in treatment-naive patients. Raltegravir also looks promising in this population.
authors.forename: Charles B
authors.initials: CB
authors.lastname: Hicks
mesh_terms: D015224:Dideoxynucleosides / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000099227:Abacavir
chemical_list: D015224:Dideoxynucleosides; D019259:Lamivudine; D018894:Reverse Transcriptase Inhibitors; D000099227:Abacavir